| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOB100 |
| Uniprot No | P04114 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1406-1606aa |
| 氨基酸序列 | NPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHLFVKEVKIDGQFRVSSF YAKGTYGLSCQRDPNTGRLNGESNLRFNSSYLQGTNQITGRYEDGTLSLT STSDLQSGIIKNTASLKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQN ALLRSEYQADY |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOB100重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Expression and characterization of recombinant human apolipoprotein B-100 in mammalian cells"*
**作者**: Yang CY et al.
**摘要**: 该研究利用哺乳动物细胞(CHO细胞)成功表达了全长人源APOB100重组蛋白，证实其能够与脂质结合形成低密度脂蛋白(LDL)类似颗粒，并保留与LDL受体结合的能力，为研究APOB100在脂代谢中的功能提供了工具。
---
2. **文献名称**: *"Production of functional recombinant apolipoprotein B-100 in Escherichia coli"*
**作者**: Pease RJ et al.
**摘要**: 通过优化大肠杆菌表达系统，研究实现了APOB100关键结构域(如LDL受体结合区域)的重组表达，并验证其抗原性和受体结合活性，为开发基于APOB100的抗体检测技术奠定了基础。
---
3. **文献名称**: *"Structural analysis of apolipoprotein B-100 by mutagenesis: Identification of residues critical for lipid binding"*
**作者**: Segrest JP et al.
**摘要**: 通过定点突变技术研究重组APOB100的结构-功能关系，发现特定氨基酸残基对其结合脂质和维持LDL颗粒稳定性至关重要，揭示了APOB100在动脉粥样硬化中的潜在分子机制。
---
(注：上述文献为示例，实际引用需根据具体研究核实作者及标题。)
**Background of APOB100 Recombinant Protein**
Apolipoprotein B-100 (APOB100) is a critical structural and functional component of lipid-transporting particles, primarily low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL). It is synthesized in the liver and plays a pivotal role in lipid metabolism by binding lipids, stabilizing lipoprotein structure, and mediating cellular uptake of LDL via interactions with the LDL receptor. APOB100 is encoded by the *APOB* gene, and mutations in this gene are linked to dyslipidemias, including familial hypercholesterolemia, underscoring its importance in cardiovascular health.
The recombinant APOB100 protein is produced using biotechnological methods, such as expression in bacterial, yeast, or mammalian cell systems, to study its biochemical properties, ligand-receptor interactions, and pathological mechanisms. Recombinant technology enables the production of high-purity, functional APOB100. bypassing challenges associated with isolating the protein from native sources. This tool has been instrumental in elucidating APOB100's role in atherosclerosis, lipid homeostasis, and its potential as a therapeutic target.
Current research focuses on APOB100's structural domains, particularly its LDL receptor-binding region, and its modulation by proteases like PCSK9. Additionally, recombinant APOB100 aids in developing diagnostic assays, lipid-lowering therapies (e.g., monoclonal antibodies or RNA-based drugs), and personalized medicine approaches for genetic lipid disorders. Challenges remain in mimicking post-translational modifications (e.g., glycosylation) during recombinant production, which are crucial for its native functionality. Nonetheless, APOB100 recombinant protein remains a vital resource for advancing cardiovascular research and therapeutic innovation.
×
